NURS 5334 FINAL PAPER TEST BANK EXAM
Q&A 2026 100% CORRECT.
⫸ Tretinoin. Answer: Normalizes keratinization, anti-inflammatory
⫸ Comedonal/mild acne. Answer: Indications for tretinoin
⫸ Severe/nodular acne. Answer: Indications for isotretinoin
⫸ Mild acne (no inflammation). Answer: Indications for benzoyl
peroxide
⫸ Clindamycin / Erythromycin (topical). Answer: Inhibits bacterial
protein synthesis
⫸ Inflammatory acne. Answer: Indications for
clindamycin/erythromycin
⫸ Azelaic Acid. Answer: Antibacterial, anti-inflammatory
⫸ Mild-moderate acne, rosacea. Answer: Indications for azelaic acid
⫸ Metronidazole (topical). Answer: Antimicrobial, anti-
inflammatory
,⫸ Rosacea. Answer: Indications for metronidazole
⫸ Doxycycline (oral). Answer: Inhibits protein synthesis
⫸ Moderate rosacea. Answer: Indications for doxycycline
⫸ 5-Fluorouracil (Efudex). Answer: Inhibits DNA/RNA synthesis
⫸ Precancerous lesions. Answer: Indications for 5-fluorouracil
⫸ Imiquimod (Aldara). Answer: Immune modulator (↑ cytokines)
⫸ Actinic keratosis, warts. Answer: Indications for imiquimod
⫸ Hydrocortisone / Triamcinolone (topical steroids). Answer: ↓
Inflammation via cytokine suppression
⫸ Atopic dermatitis, eczema. Answer: Indications for
hydrocortisone/triamcinolone
⫸ Tacrolimus (Protopic). Answer: Calcineurin inhibitor → ↓ T-cell
activation
,⫸ Chronic eczema, steroid-sparing. Answer: Indications for
tacrolimus
⫸ Tazarotene (Tazorac). Answer: Retinoid; normalizes keratinocytes
⫸ Plaque psoriasis. Answer: Indications for tazarotene
⫸ Calcipotriene (Dovonex). Answer: Vitamin D analogue → ↓
keratinocytes
⫸ Methotrexate. Answer: Folate antagonist → ↓ DNA synthesis
⫸ Severe psoriasis, arthritis. Answer: Indications for methotrexate
⫸ Pharmacodynamics (PD). Answer: Vaccines present antigen (live-
attenuated or inactivated/subunit) → APC uptake → T-cell priming →
B-cell maturation → neutralizing IgG (±mucosal IgA) and memory.
⫸ Live vaccines. Answer: Typically produce broader/longer
immunity than inactivated.
⫸ Re-immunization. Answer: Safe; reduced doses should not be
used.
, ⫸ Major absolute contraindication. Answer: Prior anaphylaxis to a
dose/component.
⫸ Pharmacokinetics (PK). Answer: No classical
absorption/distribution/elimination like small molecules. Antigen
remains largely local/intramuscular/intradermal, drains to regional
lymphatics; immune effect persists via memory cells (months-years).
⫸ Key interactions. Answer: IVIG/IG interferes with live vaccines
(e.g., MMR, varicella)—separate per ACIP timing; space live-virus
vaccines; most inactivated vaccines can be co-administered at
different sites.
⫸ Varicella. Answer: Routine childhood 2-dose series; susceptible
adults.
⫸ Zoster (RZV, Shingrix). Answer: ≥50 y (2 doses, 2-6 mo apart) for
shingles & post-herpetic neuralgia prevention.
⫸ ADEs for Varicella. Answer: Local pain/erythema; occasional
mild varicella-like rash (live).
⫸ ADEs for RZV. Answer: Injection-site pain, fever, myalgias.
⫸ Contraindications for Varicella. Answer: Live varicella
contraindicated in pregnancy and severe immunocompromise; defer
during active moderate/severe illness.
Q&A 2026 100% CORRECT.
⫸ Tretinoin. Answer: Normalizes keratinization, anti-inflammatory
⫸ Comedonal/mild acne. Answer: Indications for tretinoin
⫸ Severe/nodular acne. Answer: Indications for isotretinoin
⫸ Mild acne (no inflammation). Answer: Indications for benzoyl
peroxide
⫸ Clindamycin / Erythromycin (topical). Answer: Inhibits bacterial
protein synthesis
⫸ Inflammatory acne. Answer: Indications for
clindamycin/erythromycin
⫸ Azelaic Acid. Answer: Antibacterial, anti-inflammatory
⫸ Mild-moderate acne, rosacea. Answer: Indications for azelaic acid
⫸ Metronidazole (topical). Answer: Antimicrobial, anti-
inflammatory
,⫸ Rosacea. Answer: Indications for metronidazole
⫸ Doxycycline (oral). Answer: Inhibits protein synthesis
⫸ Moderate rosacea. Answer: Indications for doxycycline
⫸ 5-Fluorouracil (Efudex). Answer: Inhibits DNA/RNA synthesis
⫸ Precancerous lesions. Answer: Indications for 5-fluorouracil
⫸ Imiquimod (Aldara). Answer: Immune modulator (↑ cytokines)
⫸ Actinic keratosis, warts. Answer: Indications for imiquimod
⫸ Hydrocortisone / Triamcinolone (topical steroids). Answer: ↓
Inflammation via cytokine suppression
⫸ Atopic dermatitis, eczema. Answer: Indications for
hydrocortisone/triamcinolone
⫸ Tacrolimus (Protopic). Answer: Calcineurin inhibitor → ↓ T-cell
activation
,⫸ Chronic eczema, steroid-sparing. Answer: Indications for
tacrolimus
⫸ Tazarotene (Tazorac). Answer: Retinoid; normalizes keratinocytes
⫸ Plaque psoriasis. Answer: Indications for tazarotene
⫸ Calcipotriene (Dovonex). Answer: Vitamin D analogue → ↓
keratinocytes
⫸ Methotrexate. Answer: Folate antagonist → ↓ DNA synthesis
⫸ Severe psoriasis, arthritis. Answer: Indications for methotrexate
⫸ Pharmacodynamics (PD). Answer: Vaccines present antigen (live-
attenuated or inactivated/subunit) → APC uptake → T-cell priming →
B-cell maturation → neutralizing IgG (±mucosal IgA) and memory.
⫸ Live vaccines. Answer: Typically produce broader/longer
immunity than inactivated.
⫸ Re-immunization. Answer: Safe; reduced doses should not be
used.
, ⫸ Major absolute contraindication. Answer: Prior anaphylaxis to a
dose/component.
⫸ Pharmacokinetics (PK). Answer: No classical
absorption/distribution/elimination like small molecules. Antigen
remains largely local/intramuscular/intradermal, drains to regional
lymphatics; immune effect persists via memory cells (months-years).
⫸ Key interactions. Answer: IVIG/IG interferes with live vaccines
(e.g., MMR, varicella)—separate per ACIP timing; space live-virus
vaccines; most inactivated vaccines can be co-administered at
different sites.
⫸ Varicella. Answer: Routine childhood 2-dose series; susceptible
adults.
⫸ Zoster (RZV, Shingrix). Answer: ≥50 y (2 doses, 2-6 mo apart) for
shingles & post-herpetic neuralgia prevention.
⫸ ADEs for Varicella. Answer: Local pain/erythema; occasional
mild varicella-like rash (live).
⫸ ADEs for RZV. Answer: Injection-site pain, fever, myalgias.
⫸ Contraindications for Varicella. Answer: Live varicella
contraindicated in pregnancy and severe immunocompromise; defer
during active moderate/severe illness.
